The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations

被引:10
作者
Ivanova, Anastasia [1 ]
Israel, Elliot [1 ]
LaVange, Lisa M. [1 ]
Peters, Michael C. [1 ]
Denlinger, Loren C. [1 ]
Moore, Wendy C. [1 ]
Bacharier, Leonard B. [1 ]
Marquis, M. Alison [1 ]
Gotman, Nathan M. [1 ]
Kosorok, Michael R. [1 ]
Tomlinson, Chalmer [1 ]
Mauger, David T. [1 ]
Georas, Steve N. [1 ]
Wright, Rosalind J. [1 ]
Noel, Patricia [1 ]
Rosner, Gary L. [1 ]
Akuthota, Praveen [1 ]
Billheimer, Dean [1 ]
Bleecker, Eugene R. [1 ]
Cardet, Juan Carlos [1 ]
Castro, Mario [1 ]
DiMango, Emily A. [1 ]
Erzurum, Serpil C. [1 ]
Fahy, John V. [1 ]
Fajt, Merritt L. [1 ]
Gaston, Benjamin M. [1 ]
Holguin, Fernando [1 ]
Jain, Sonia [1 ]
Kenyon, Nicholas J. [1 ]
Krishnan, Jerry A. [1 ]
Kraft, Monica [1 ]
Kumar, Rajesh [1 ]
Liu, Mark C. [1 ]
Ly, Ngoc P. [1 ]
Moy, James N. [1 ]
Phipatanakul, Wanda [1 ]
Ross, Kristie [1 ]
Smith, Lewis J. [1 ]
Szefler, Stanley J. [1 ]
Teague, W. Gerald [1 ]
Wechsler, Michael E. [1 ]
Wenzel, Sally E. [1 ]
White, Steven R. [1 ]
机构
[1] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA
关键词
Master protocol; platform trial; covariate adaptive randomization; adaptive enrichment; compex; severe asthma; BENRALIZUMAB; SUBGROUP; RECEPTOR;
D O I
10.1080/10543406.2020.1821705
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The Precision Interventions for Severe and/or Exacerbation-prone Asthma (PrecISE) study is an adaptive platform trial designed to investigate novel interventions to severe asthma. The study is conducted under a master protocol and utilizes a crossover design with each participant receiving up to five interventions and at least one placebo. Treatment assignments are based on the patients' biomarker profiles and precision health methods are incorporated into the interim and final analyses. We describe key elements of the PrecISE study including the multistage adaptive enrichment strategy, early stopping of an intervention for futility, power calculations, and the primary analysis strategy.
引用
收藏
页码:1026 / 1037
页数:12
相关论文
共 27 条
  • [1] I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
    Barker, A. D.
    Sigman, C. C.
    Kelloff, G. J.
    Hylton, N. M.
    Berry, D. A.
    Esserman, L. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (01) : 97 - 100
  • [2] Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
    Bleecker, Eugene R.
    FitzGerald, J. Mark
    Chanez, Pascal
    Papi, Alberto
    Weinstein, Steven F.
    Barker, Peter
    Sproule, Stephanie
    Gilmartin, Geoffrey
    Aurivillius, Magnus
    Werkstrom, Viktoria
    Goldman, Mitchell
    [J]. LANCET, 2016, 388 (10056) : 2115 - 2127
  • [3] Futility stopping in clinical trials, optimality and practical considerations
    Chang, Yen
    Song, Tianhao
    Monaco, Jane
    Ivanova, Anastasia
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2020, 30 (06) : 1050 - 1059
  • [4] International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
    Chung, Kian Fan
    Wenzel, Sally E.
    Brozek, Jan L.
    Bush, Andrew
    Castro, Mario
    Sterk, Peter J.
    Adcock, Ian M.
    Bateman, Eric D.
    Bel, Elisabeth H.
    Bleecker, Eugene R.
    Boulet, Louis-Philippe
    Brightling, Christopher
    Chanez, Pascal
    Dahlen, Sven-Erik
    Djukanovic, Ratko
    Frey, Urs
    Gaga, Mina
    Gibson, Peter
    Hamid, Qutayba
    Jajour, Nizar N.
    Mauad, Thais
    Sorkness, Ronald L.
    Teague, W. Gerald
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (02) : 343 - 373
  • [5] The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis
    de Wit, Helena M.
    te Groen, Maarten
    Rovers, Maroeska M.
    Tack, Cees J.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (01) : 301 - 314
  • [6] The Placebo Effect in Asthma
    Dutile, Stefanie
    Kaptchuk, Ted J.
    Wechsler, Michael E.
    [J]. CURRENT ALLERGY AND ASTHMA REPORTS, 2014, 14 (08)
  • [7] FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]
  • [8] A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials
    Fuhlbrigge, Anne L.
    Bengtsson, Thomas
    Peterson, Stefan
    Jauhiainen, Alexandra
    Eriksson, Goran
    Da Silva, Carla A.
    Johnson, Anthony
    Sethi, Tariq
    Locantore, Nicholas
    Tal-Singer, Ruth
    Fageras, Malin
    [J]. LANCET RESPIRATORY MEDICINE, 2017, 5 (07) : 577 - 590
  • [9] Hedaya MA., 2012, BASIC PHARMACOKINETI
  • [10] HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800